Navigation Links
Sinovac Participates in Two Investor Conferences in November
Date:10/27/2010

BEIJING, Oct. 27 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, announced today that Mr. Jacob Ho, Acting Chief Financial Officer, Ms. Vanessa Wu, Senior Financial Manager and Ms. Helen Yang, Investor Relations Manager, are scheduled to present at two upcoming investor conferences to be held in early November.

  • Goldman Sachs China Investment Frontier Conference 2010, Beijing, China, November 1-2: Sinovac is participating in one-on-one and group meetings on November 1
  • Bank of America Merrill Lynch China Investment Summit, Beijing China, November 1-5: Sinovac is participating in one-on-one meetings on November 3

  • About SinovacSinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases including hepatitis A, seasonal influenza, H5N1 (bird flu) pandemic influenza and H1N1 influenza. In 2009, Sinovac was the first company worldwide to receive approval for its H1N1 influenza vaccine, PANFLU.1, and has received the orders from the Chinese Central Government pursuit to the government stockpiling program. The Company is developing a number of new vaccine products, including vaccines for pneumococcal conjugate, enterovirus 71 (EV71) (against Hand, Foot & Mouth Disease), Japanese Encephalitis, animal and human rabies, HIB and epidemic meningitis, chickenpox, mumps and rubella. Its wholly owned subsidiary, Tangshan Yian, is focusing on the research, development, manufacturing and commercialization of animal vaccines and has completed the field trials for an independently developed inactivated animal rabies vaccine, which is anticipated to be launched into market in 2011.

    Safe Harbor StatementThis announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by words or phrases such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Among other things, the business outlook and quotations from management in this press release contain forward-looking statements. Statements that are not historical facts, including statements about Sinovac's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement. Sinovac does not undertake any obligation to update any forward-looking statement, except as required under applicable law.Helen YangSinovac Biotech Ltd.Tel:  +86-10-8279-9871Fax:  +86-10-6296-6910Email: info@sinovac.com Investors:Stephanie Carrington/Amy GlynnThe Ruth GroupTel:  +1-646-536-7017/7023Email: scarrington@theruthgroup.comaglynn@theruthgroup.comMediaJason RandoThe Ruth GroupTel:  +1-646-536-7025Email:  jrando@theruthgroup.com
    '/>"/>

    SOURCE Sinovac Biotech Ltd.
    Copyright©2010 PR Newswire.
    All rights reserved

    Related biology technology :

    1. Sinovac Biotech Ltd. Schedules 2007 Annual Meeting of Shareholders
    2. Sinovac Reports Record Second Quarter 2008 Unaudited Financial Results
    3. Sinovac to Present at the Susquehanna Financial Groups Second Annual Beijing Management Summit Conference
    4. Sinovac Adjourns Annual General Meeting
    5. Sinovac Launches Seasonal Influenza Vaccine Anflu(R) for 2008-2009 Flu Season
    6. Sinovac Initiates Clinical Trials for Inactivated Hepatitis A Vaccine in Ukraine
    7. Sinovac to Present at the 2008 UBS Global Life Sciences Conference
    8. Sinovac Biotech Holds 2007 Annual General Meeting
    9. Sinovacs Credit Rating Upgraded to AAZ, Second Highest Rating
    10. Sinovac to Participate in Two Upcoming Investor Conferences
    11. Sinovac Named to Deloitte Technology Fast 50 China
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:6/23/2016)... FRANCISCO , June 23, 2016   EpiBiome ... has secured $1 million in debt financing from Silicon ... ramp up automation and to advance its drug development ... its new facility. "SVB has been an ... beyond the services a traditional bank would provide," said ...
    (Date:6/23/2016)...  Blueprint Bio, a company dedicated to identifying, protecting ... has closed its Series A funding round, according to ... "We have received a commitment from Forentis Fund that ... meet our current goals," stated Matthew Nunez . ... complete validation on the current projects in our pipeline, ...
    (Date:6/23/2016)... ... June 23, 2016 , ... Velocity Products, ... tools designed, tuned and optimized exclusively for Okuma CNC machining centers at The ... of a collaboration among several companies with expertise in toolholding, cutting tools, machining ...
    (Date:6/22/2016)... NEW YORK , June 22, 2016 /PRNewswire/ ... the growing next generation sequencing (NGS) market include ... adoption of smaller sequencers.  More accessible and affordable ... led to growing demand for consumables including sample ... The Market for Sample Preparation for Next ...
    Breaking Biology Technology:
    (Date:5/20/2016)... 20, 2016  VoiceIt is excited to announce ... By working together, VoiceIt and VoicePass ... and VoicePass take slightly different approaches to voice ... security and usability. ... new partnership. "This marketing and technology ...
    (Date:5/12/2016)... May 12, 2016 WearablesResearch.com , a ... the overview results from the Q1 wave of its ... wave was consumers, receptivity to a program where they ... a health insurance company. "We were surprised ... says Michael LaColla , CEO of Troubadour Research, ...
    (Date:5/3/2016)... 3, 2016  Neurotechnology, a provider of high-precision ... Automated Biometric Identification System (ABIS) , a complete ... MegaMatcher ABIS can process multiple complex biometric transactions ... of fingerprint, face or iris biometrics. It leverages ... and MegaMatcher Accelerator , which have been ...
    Breaking Biology News(10 mins):